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Abstract 
In a previous study, Protein Kinase C iota (PRKCI) emerged as an important candidate gene for 
glioblastoma stem-like cell (GSC) survival. Here we show that PKCι is overexpressed and 
activated in patient derived GSCs compared with normal neural stem cells and normal brain 
lysate, and that silencing of PRKCI in GSCs causes apoptosis, along with loss of clonogenicity 
and reduced proliferation. Notably, PRKCI silencing reduces tumor growth in vivo in a xenograft 
mouse model. PKCι has been intensively studied as a therapeutic target in non-small cell lung 
cancer, resulting in the identification of an inhibitor, aurothiomalate (ATM), which disrupts the 
PKCι/ERK signaling axis. However, we show that, although sensitive to pharmacological 
inhibition via a pseudosubstrate peptide inhibitor, GSCs are much less sensitive to ATM, 
suggesting that PKCι acts along a different signaling axis in GSCs. Gene expression profiling of 
PRKCI-silenced GSCs revealed a novel role of the Notch signaling pathway in PKCι mediated 
GSC survival. A proximity ligation assay showed that Notch1 and PKCι are in close proximity in 
GSCs. Targeting PKCι in the context of Notch signaling could be an effective way of attacking 
the GSC population in glioblastoma. 
 
Introduction 
Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults. The 
median survival of patients on current treatment regimes, which most commonly consist of 
surgical resection with adjuvant temozolomide (TMZ) and radiotherapy, is only 14.6 months [1]. 
Traditionally, GBM has been investigated using immortalized, serum-cultured adherent cell lines, 
which represent the highly proliferative tumor bulk. However, more recently, it has been shown 
that GBM is initiated and maintained by a small sub-population of cells which is capable of self-
renewal and recapitulation of the original tumor in non-obese diabetic/severe combined 
immunodeficient (NOD-SCID) mice [2, 3]. These so-called glioblastoma stem-like cells (GSCs) 
can be enriched from patient derived tumor material by culturing in serum free conditions 
supplemented with basal FGF and EGF. It has been suggested that GBM cells cultured in this 
way more closely mirror the phenotype and genotype of primary tumors than do serum-cultured 
cell lines [4, 5]. Furthermore, it has been shown that GSCs are linked to tumor recurrence and 
are enriched in recurrent malignant gliomas. Indeed, GSCs are more resistant to radio- and 
chemotherapy than bulk tumor cells [6-8], suggesting that targeting GSCs could be tantamount 
to improving therapy for GBM.  
In recent years, much progress has been made in understanding gene expression patterns in 
many tumor types, with GBM being no exception [9-11]. Although such data have proved 
invaluable for discovering potential target genes for novel GBM therapies, the fact remains that 
gene expression does not necessarily reflect gene function. This is an issue which can be 
resolved by phenotypic screening studies, for example, by systematically silencing different 
genes and assessing a particular phenotypic effect. We have previously carried out one such 
screen, whereby the kinome and phosphatome was silenced in GSCs using a short hairpin RNA 
(shRNA) library. This revealed the importance of various genes for the survival of GSCs, 
including Protein Kinase C iota (PRKCI) [12].  
PKCι is a member of the atypical Protein Kinase C (PKC) family, along with Protein Kinase C 
Zeta (PKCζ). PRKCI has been classified as an oncogene in various forms of human cancer [13-
18], and its overexpression has been found to correlate with poor prognosis in lung and 
pancreatic cancer [19, 20]. Atypical PKC has also recently been shown to be activated and 
linked to NF-κB activation in GBM [21]. 
Here we decipher the function of PKCι in the survival of GSCs, demonstrating a new role for 
PKCι in glioblastoma in the Notch signaling mediated survival of GSCs. 
Materials and Methods 
Cell Culture Conditions 
The GSC lines NCH421k, NCH644 and NCH441 were derived from primary GBM patients who 
underwent surgical resection according to the research proposals approved by the Institutional 
Review Board at the Medical Faculty of Heidelberg. Tissues were enzymatically dissociated and 
cells were cultivated as floating neurospheres in serum-free DMEM/F-12 medium, supplemented 
with 20 % BIT-admixture (Pelo Biotech) and basal fibroblast growth factor (Biomol) and 
epidermal growth factor (Life Technologies) at 20 ng/ml each. Genotypic and phenotypic studies 
have been carried out in previous investigations [5, 22]. Passaging and seeding was carried out 
by dissociation with accutase (Sigma-Aldrich). Human fetal neural stem cells were a kind gift 
from Dr. C Watts at the Department of Clinical Neurosciences, University of Cambridge. They 
were established from 12–14 week old human post-mortem fetal tissue as described by Iovino et 
al [23] and were cultured in the same serum-free medium conditions as the GSCs. A549 cells 
were cultured adherently in DMEM medium supplemented with 10 % FCS and 1 % 
penicillin/streptomycin. 
Lentivirus Production and Transduction 
HEK293T cells were seeded into 10 cm dishes and cotransfected with the plko.1 containing 
shRNA plasmids from The RNAi Consortium (TRC) and the packaging plasmids (pMD2.G, 
psPAX2) using Trans-IT transfection reagent (Mirus Bio). Virus containing medium was collected 
and filtered 72 hours after transfection and concentrated by ultracentrifugation for 1.5 hours at 
25000 rpm. The titer was determined by FACS analysis using the plko.1-TurboGFP control 
plasmid. Non targeting shRNA was used as a negative control. PRKCI-sh1 and PRKCI-sh2 were 
used in functional studies. shRNA sequences are detailed in table S1. For transduction, GSCs 
were seeded at a density of 50000 cells per ml and transduced with a multiplicity of infection 
(MOI) of 5. plko.1 TurboGFP containing lentivirus was used to estimate transduction efficiency 
via FACS analysis. Experiments were discarded if <70 % of cells were green. 
Inhibitor Assay 
Cells were seeded in 96 well plates at a density of 5000 cells per well. Sodium aurothiomalate 
(Sigma-Aldrich) or aPKC pseudosubrate (myristoylated) (Enzo Life Sciences)  were applied at 
various concentrations and viability was measured after 3 days using a CellTiter-Glo® assay 
(Promega), according to the manufacturer’s protocol. 
Cell Death 
Apoptosis of GSCs was assessed 4 days after transduction in 96 well plates using a Caspase 
Glo® 3/7 assay (Promega) according to the manufacturer’s protocol. Additionally, apoptosis was 
measured 7 days after transduction in 6 well plates using 7-amino-actinomycin (7-AAD) and 
annexin V staining. GSCs were dissociated with accutase and incubated with annexin V binding 
buffer containing 10 % 7-AAD and 10 % annexin V-PE (BD Biosciences, Heidelberg, Germany). 
Annexin V and 7-AAD positive cells were measured using a FACSCanto II (BD Biosciences) and 
quantified with FACSDiva Software (BD Biosciences). Annexin V-positive cells (early apoptotic), 
7AAD positive cells (necrotic) and doubly stained cells with both annexin V and 7-AAD (late 
apoptotic or necrotic) were deemed to be dead. For the rescue assay, NCH644-pLenti PGK V5-
LUC Neo cells containing genes for the inducible expression of PRKCI-shRNA or NT-shRNA 
were transduced with pLVX-PRKCI at an MOI of 20. shRNA expression was induced by addition 
of 1 µg/ml doxycycline to the medium every two days. 5 days after doxycycline began to be 
applied, cell death was measured by propidium iodide staining and FACS analysis using a 
FACSCanto II. 
Proliferation 
Proliferation was measured using the Click-it EdU cell proliferation assay (Life Technologies) 
according to the manufacturer’s protocol, whereby 10 µM EdU was added to the medium 72 
hours after transduction. Incorporated EdU was detected 16 hours later by flow cytometry on a 
FACSCanto II after conjugation with Alexa Fluor 488. Data were analysed using the FACSDiva 
software. 
Extreme Limiting Dilution Neurosphere Formation Assay 
Two days after transduction with PRKCI-shRNA or NT-shRNA lentiviral particles, NCH421k cells 
were seeded into 96 well plates with densities of 1, 5, 10, 25 and 50 cells per well via a FACS 
sorter (FACSAria I, BD Biosciences). Spheres containing at least 5 cells were counted at day 10 
after transduction the data analysed using the extreme limiting dilution assay (ELDA) software, 
available at http://bioinf.wehi.edu.au/software/elda/. 
Western Blot Analysis 
Cell lysates were quantified using a BCA assay, separated in 4-12 % polyacrylamide precast 
gels (Life Technologies, Darmstadt, Germany) under reducing conditions and transferred onto a 
PVDF membrane. Immunoreactive bands were detected using ECL or ECL Plus Substrate 
(Thermo Fischer Scientific). Band intensity was quantified using Image J software. Normal brain 
tissue lysate was obtained from BioChain. Primary antibodies PKCι (60175, BD Transduction 
Laboratories), Phospho-PKCι (07-881, Upstate Cell Signaling Solutions), PKCζ (9368, Cell 
Signaling Technologies), PathScan Multiplex Western Cocktail I (for P-ERK) (5301, Cell 
Signaling Technologies),  Notch Intracellular Domain (4147, Cell Signaling Technologies), HES5 
(ab194111, Abcam) were used at a 1:1000 dilution and α-tubulin (T6199, Sigma Aldrich) was 
used at a 1:5000 dilution. Horseradish peroxidase (HRP) coupled secondary antibodies (Abcam) 
were used at dilutions of 1:7500. 
RNA Extraction and Quantitative Real-time PCR Analysis 
1 µg RNA was pretreated with DNAse I (Life Technologies) and reverse transcribed by 
Superscript II (Life Technologies) according to the manufacturer’s protocol. Complementary 
cDNA was measured using Absolute SYBR Green ROX Mix (ABgene) in technical triplicate 
using an ABI PRISM 7900HT thermal cycler (Applied Biosystems). cDNA levels were quantified 
based on the standard curves produced from a serial dilution of cDNA transcribed from 
NCH421k RNA and normalization to three housekeeper genes (ARF1, DCTN2 and HPRT). 
Oligonucleotide sequences are detailed in table S2. 
Microarray Analysis 
NCH421k and NCH644 cells were transduced in three independent experiments with shNT and 
PRKCI-sh2. After 4 days, RNA was extracted from cells using the RNAeasy Mini Kit (Qiagen) 
according to the manufacturer’s protocol and examined for integrity using an Agilent 2100 
Bioanalyzer (Agilent Technologies). Gene expression profiling was performed using the 4x44K 
Whole Human Genome Oligo Microarray (Agilent Technologies). Microarray slides were 
scanned on an Agilent Microarray Scanner G25505B and data extracted using the Agilent 
Feature Extraction software version 9.1. Data processing followed using ChipYard (developed 
in-house, www.dkfz.de/genetics/ChipYard). Statistical significance of differential gene 
expression was determined by applying a linear model and an empirical Bayes moderated t-test 
statistic to each gene tested, followed by Benjamini-Hochberg correction for multiple testing [24]. 
Significantly deregulated pathways were identified using Ingenuity software (Ingenuity® Pathway 
Analysis (Qiagen) www.qiagen.com/ingenuity). 
Gene Set Enrichment Analysis 
Gene set enrichment analysis was performed at www.broadinstitute.org/gsea. Genes were pre-
ranked based on the mean fold change and analyzed for the enrichment of the 
signaling_by_Notch signature from Reactome, as listed in the Molecular Signatures Database 
(http://www.broadinstitute.org/gsea/msigdb). Quantification of enrichment of the signature genes 
near the top of the ordered list of genes followed using a running-sum statistic, resulting in an 
enrichment score. The false discovery rate (FDR) q-value was used to set a significant 
threshold.  
Proximity Ligation Assay (PLA) 
NCH421k cells were grown adherently on poly-D-lysine/laminin coated coverslips. Cells were 
fixed with 4 % PFA and permeabilized with 0.1 % Triton–X100. From here, the Duo Link PLA 
Starter Kit (Sigma Aldrich) was used according to the manufacturer’s protocol. Briefly, the cells 
were blocked for 30 min at 37oC and PKCι (sc-727, Santa Cruz) and/or Notch1 (sc-6014, Santa 
Cruz Biotechnology) antibodies were incubated at 4oC overnight at 1:100 dilutions. Single 
antibodies were used to control for background signal. After washing, PLA probes were 
incubated for 1 hour at 37oC, followed by ligation and amplification reactions for 30 min and 100 
min respectively. A DAPI containing mounting medium was applied, and the cells were imaged 
using a Zeiss Axioplan 2 microscope. 5 images per condition were made at 20 x magnification 
and the mean number of PLA signals per cell determined. PLA signals were only counted if they 
were in a cell, as estimated by the locations of the DAPI stained nuclei.  
In vivo Tumor Propagation 
NCH644 GSCs were transduced with lentiviral particles carrying the pLenti PGK V5-LUC Neo 
plasmid (MOI 1), and transduced cells were selected under 400 µg/ml G418. shNT and PRKCI-
sh2 shRNA was cloned into the Tet-pLKO-puro vector and lentiviral particles produced as 
described above. NCH644-pLenti PGK V5-LUC Neo cells were transduced (MOI 1) and selected 
under 2 µg/ml puromycin. Six week old NOD-SCIDγ mice were obtained from the animal facility 
at the DKFZ. All animal experiments were performed according to animal welfare regulations 
and were approved by the responsible authorities (Regierungspräsidium Karlsruhe, approval 
number G64-14). NCH644-pLenti PGK V5-LUC Neo cells containing genes for the inducible 
expression of PRKCI-shRNA or NT-shRNA were treated with accutase and 100000 cells were 
injected into the striatum of the mice. Tumor development was measured twice weekly and 2 
mg/l doxycycline was administered ad libitum after tumors had reached radiances of at least 
220000 but less than 1300000 flux p/s. Tumor growth was monitored using an IVIS Lumina Pre-
clinical in vivo Imaging System (Perkin Elmar) until the development of neuropathological 
symptoms, which were confirmed blindly by two independent scientists. 
Immunohistochemistry 
After perfusion with 10 % (w/v) formaldehyde, mouse brains were sectioned coronally, 
dehydrated in a STP 120 spin tissue processor (Thermo Fischer Scientific) and embedded in 
paraffin. Sections (4 μm thickness) were cut and mounted onto glass slides, deparaffinized in 
xylene and rehydrated in a descending series of alcohols. Slides were treated with PKCι (60175, 
BD Transduction Laboratories) or HES5 (ab194111, Abcam) primary antibodies overnight at 4oC 
and incubated with a HRP conjugated secondary antibody for 1 h at room temperature. Staining 
was visualized using the avidin-biotin peroxidase system (Vector Laboratories) and freshly 
prepared diaminobenzidine as a chromogen (Dako Deutschland). Slides were counterstained 
with haematoxylin, dehydrated and mounted. Images were made using a Zeiss Axioplan 2 
microscope. 
Results 
PKCι is Overexpressed and Activated in GSCs 
Using a kinome-wide RNA interference (RNAi) screen, we identified PRKCI as a gene whose 
silencing induces apoptosis in GSCs [12]. In order to investigate the specificity of PRKCI 
expression to GSCs, PKCι protein levels were measured in three different GSCs derived from 3 
different patients (NCH421k, NCH644 and NCH441) and compared with human fetal neural 
stem cells (HFNSCs) and normal brain extract. Protein levels of PKCι and especially phospho-
PKCι (T555) were much lower in the HFNSCs and normal total brain extract (figure 1a). 
However, interestingly, there were no significant differences in mRNA levels between the GSC 
lines, HFNSCs and a pool of normal brain mRNA (Figure 1b). Nor are there significant 
differences in expression to be found in publically available expression datasets comparing 
glioma of different grades and controls (figure 1c). 
PRKCI silencing Induces Apoptosis and Reduces Proliferation and Clonogenicity in GSCs 
In order to investigate phenotypic changes upon PRKCI silencing, GSCs were transduced with 
two different shRNAs targeting PRKCI (sh1 and sh2) or non-targeting shRNA (shNT) (figures 2a 
and S1a-c). As demonstrated in a Caspase Glo® apoptosis assay 4 days after transduction of 
GSC lines NCH421k, NCH644 and NCH441, apoptosis was induced upon PRKCI silencing 
(figure 2b). This was confirmed in GSC lines NCH421k and NCH644 using an annexin V/7AAD 
apoptosis assay 7 days after transduction, which revealed that the percentage of annexin 
V/7AAD negaitive (i.e. living) cells was significantly decreased upon PRKCI silencing in these 
GSC lines (figure S1 d and e). In order to assess the specificity of this phenomenon, NCH421k, 
NCH644 and NCH441 GSCs and  and HFNSCs were transduced with shNT, sh1 or sh2 and cell 
viability was assessed 5 days later using a CellTiter-Glo® assay (figure 2c). Notably, in sh2 
transduced cells, where the knockdown is the strongest, only the viability of the GSCs is 
significantly reduced, whereas sh1 causes a significant reduction in the viability of both GSCs 
and HFNSCs. A possible explanation for this is that sh1 could have off-target effects. As PKCι 
has a similar sequence (72 % homology) to the other atypical protein kinase C, Protein Kinase C 
Zeta (PKCζ), it was determined whether the shRNAs against PRKCI also cause a reduction in 
protein levels of PKCζ. Western blot analysis showed that sh1 causes a reduction of PKCζ by 
about 50 % whereas sh2 does not affect the levels at all (figures S2a and b). Interestingly, 
although PKCζ protein levels seem to be very low in HFNSCs, levels are higher in normal brain 
extract than in the GSC lines NCH421k and NCH441 (figure S2c). Furthermore, microarray data 
has shown that mRNA levels of PKCζ are significantly higher in normal brain than in GBM 
samples (figure S2d) [25]. 
Proliferation of living cells was measured 4 days after transduction by FACS assessment of EdU 
incorporation into NCH421k, NCH644 and NCH441 GSCs (figure 2d). Proliferation was 
significantly reduced upon PRKCI silencing in all GSC lines with both sh1 and sh2, suggesting 
that PRKCI knockdown causes cells to stop proliferating before they undergo apoptosis. An 
extreme limiting dilution assay showed that PRKCI silencing decreases the capacity of NCH421k 
cells to form neurospheres, which could suggest a loss of clonogenicity (figure S1f).  
Effects of Pharmacological Inhibition of PKCι on GSC Viability 
The effect of pharmacological inhibition of PKCι on GSC viability was assessed using a 
myristoylated atypical PKC pseudosubstrate peptide (aPKC-PSP), which blocks phosphorylation 
of PKCι at Thr555, and hence prevents the kinase from attaining its active conformation [26, 27]. 
NCH421k, NCH644 and NCH441 GSCs were treated with increasing concentrations of aPKC-
PSP for 3 days and a reduction of viability was observed in all 3 cell lines (with an IC50 of around 
20 µM for NCH421k and NCH441, and around 100 µM for NCH644) (figure 3a, upper panel). A 
reduction of the activity of PKCι upon incubation with the compound was confirmed by Western 
blotting with the P-PKCι (Thr555) antibody (figure 3a, lower panel). 
A further inhibitor of PKCι, Aurothiomalate (ATM), was also tested for its activity against GSCs. 
In non small cell lung cancer (NSCLC) cells, it has been shown that ATM disrupts the interaction 
between PKCι and one of its binding partners, Par6 [28]. In order to test whether PKCι can be 
targeted in this way in GSCs, NCH421k, NCH644 and NCH441 GSCs were treated with 
increasing concentrations of ATM for 3 days. Lung cancer cell line A549 was used as a positive 
control, although it should be noted that other lung cancer cell lines have been reported to be 
even more sensitive to ATM [29]. It was found that ATM reduced the viability of A549 cells with 
an IC50 of around 30 µM, whereas GSCs were unaffected at this concentration (figure 3b, upper 
panel). Treatment of A549 with ATM resulted in a dose dependent reduction in phospho-ERK 
levels, which indicates that the compound does indeed disrupt the interaction of PKCι with Par6, 
as ERK is a downstream target of this signaling axis. P-ERK levels were not reduced in 
NCH421k GSCs upon treatment with ATM (figure 3 b, lower panel). Taken together, this 
indicates that PKCι facilitated GSC survival is likely to be mediated differently in GSCs than in 
NSCLC cells. 
Gene Expression Profiling After PRKCI Silencing Implicates the Notch Signaling Pathway 
in PRKCI Mediated GSC Survival 
In order to investigate the crucial role of PRKCI in GSC survival, gene expression microarray-
based transcriptome analysis was conducted on GSCs transduced for 4 days with PRKCI-sh2 
compared with GSCs transduced with shNT. PRKCI-sh2 was selected due to its high efficiency 
of silencing and its specificity for PRKCI (rather than PRKCZ). Three biological replicates were 
performed, twice in NCH421k and once in NCH644 GSCs. Empirical Bayes Moderated t-testing 
revealed 3367 differentially regulated genes (adj. p value < 0.05). The full dataset can be found 
at the Gene Expression Omnibus public functional genomics data repository with the GEO 
number GSE77030.  Using a threshold of a fold change of 1.5, the 395 most deregulated genes 
were analysed using the Ingenuity® Pathway Analysis software (IPA®, QIAGEN Redwood City, 
www.qiagen.com/ingenuity). The most significantly deregulated pathway was the Notch 
signaling pathway, known to be involved in stemness and self renewal (figure 4a). 
In addition, gene set enrichment analysis, comparing the expression data to a Notch signaling 
signature of 103 genes involved in the pathway from Reactome 
(http://www.broadinstitute.org/gsea/msigdb), revealed that the downregulated genes upon 
PRKCI silencing are significantly enriched in genes from this signature (figure 4b). 
The results of the gene expression profiling were validated by quantitative real-time polymerase 
chain reaction (qRT-PCR) analysis of the top 4 downregulated Notch pathway genes (HES5, 
NOTCH2, NOTCH1 and RBPJ) upon silencing of PRKCI for 4 days in GSCs cells using sh1 and 
sh2. Levels of all 4 Notch genes were significantly downregulated in NCH421k cells when 
PRKCI is silenced using either shRNA (figure 4c). Figure S3a also shows that HES5 mRNA 
levels were also reduced upon PRKCI silencing in NCH644 and NCH441 GSCs. Furthermore, a 
dramatic reduction in Notch intracellular domain (NICD) protein levels, which is a cleavage 
product released when Notch signaling is active, upon PRKCI silencing could be observed via 
Western blot analysis (figure 4d and S3b). Notably, pharmacological inhibition of PKCι in 
NCH421k GSCs using the aPKC-PSP, which prevents the activation of PKCι by blocking the 
phosphorylation of the activating threonine residue (Thr555), also caused a reduction in Notch 
signaling, as demonstrated by a reduction in NICD levels (figure 4e). Conversely, PKCι inhibition 
by disruption of the interaction of the kinase with Par6 by ATM in NCH42k1 GSCs did not lead to 
a reduction of Notch signaling (figure S3c). 
In order to determine whether PKCι is in close spatial proximity to Notch1 in GSCs, which would 
suggest an interaction between the two proteins, an in situ proximity ligation assay was carried 
out. An enrichment of PLA signals could be detected when both PKCι and Notch1 antibodies 
were incubated with GSCs, compared with when only one of the antibodies was bound (figure 
4e and S3c).  
Finally, a rescue study was carried out, whereby stable NCH644 cells lines expressing 
doxycycline inducible shNT or sh2 were additionally transduced with a plasmid constitutively 
expressing PRKCI (figure 5a). Whereas cell death was induced in cells which do not 
overexpress PKCι 5 days after treatment with doxycycline, the overexpressing cells were not 
affected (figure 5b, upper panel). Furthermore, the reduction in the protein level of Notch 
signaling target gene HES5 induced by PRKCI-sh2 was rescued in the cells in which PRKCI was 
overexpressed (figure 5b, lower panel). This indicates that cell death and the reduction of Notch 
signaling are specifically caused by the silencing of PRKCI and not due to off-target effects.  
Silencing of PRKCI in vivo Reduces Notch Signaling and Slows Tumor Growth  
With the aim of investigating whether PRKCI silencing can affect GBM growth in vivo, GSCs 
stable for doxycycline inducible expression of shNT- or PRKCI-sh2 were injected into the 
striatum of NOD-SCID mice. The cells also expressed luciferase, allowing tumor growth to be 
monitored via bioluminescence detection. Sh2 was chosen as it results in the highest and most 
specific knockdown, and cell line NCH644 was selected as it has been shown to grow highly 
aggressively and invasively, making it an appropriate model of GBM [30]. Silencing of PRKCI via 
ad libitum administration of doxycycline resulted in the tumors growing more slowly (figure 6a), 
and increased survival of the mice (figure 6b), compared with those whose tumors expressed 
shNT or where the shPRKCI expression was not induced. However, all mice eventually 
succumbed to the tumor, indicating that PRKCI silencing alone is not enough to cause tumor 
regression in this case. Immunohistological staining of the tumors confirmed that doxycycline 
administration indeed reduced PKCι levels in the tumor, although there appears to be some 
residual protein expression (6c, upper panel). Crucially, protein levels of the Notch signaling 
target protein HES5 are also markedly reduced in the tumors in which PKCι expression was 
depleted, suggesting that the slowed tumor growth was mediated via a reduction in Notch 
signaling (figure 6c, lower panel).  
Discussion 
We have previously identified PRKCI as an important gene for GSC survival in a kinome and 
phosphatome wide shRNA screen [12]. In this study, we have built on this finding and show a 
cancer specific expression and activation of PKCι in GSCs compared with normal neural stem 
cells and normal brain lysate. We investigate the function of PRKCI in GSCs and a gene 
expression profiling approach has identified a link between PRKCI and Notch signaling. Most 
notably, silencing PRKCI in a xenograft glioblastoma mouse model slowed tumor growth and 
prolonged survival, suggesting that PKCι would be a good therapeutic target in GBM.  
PKCι, along with PKCζ, is a member of the atypical protein kinase C (aPKC) family of proteins, 
and has been shown to be overexpressed and overactivated in a range of cancer entities. 
Although mRNA levels of PRKCI are not increased in GBM according to our experiments and 
publicly available microarray data, we here demonstrate overexpression and activation of PKCι 
on the protein level in GSCs compared with normal neural stem cells and normal brain extract. 
Supportive of this, in a recent study, Kusne et al. demonstrated that aPKC abundance inversely 
correlates with glioblastoma survival by staining human brain tissue and comparing aPKC 
expression to patient survival data  [21]. The discrepancy we observe between PKCι mRNA and 
protein levels in GSCs has been observed in other studies of PKCι in glioblastoma [21, 25, 31], 
and raises the question of how PKCι protein levels are regulated. Further experiments would be 
required to determine whether the kinase is regulated on the translational or post-translational 
level. However, as we have shown that PKCι is more highly phosphorylated in GSCs compared 
with normal neural stem cells and normal brain extract, it could be conceivable that the kinase is 
stabilized by cancer-dependent phosphorylation or perhaps yet unknown post-translational 
modifications.  
We have shown that pharmacological inhibition of PKCι using a myristoylated pseudosubstrate 
peptide reduced the viability of GSCs in vitro. The pseudosubstrate peptide inhibited the 
phosphorylation of PKCι at Thr555, and is thought to render the kinase inactive in this way [26, 
27]. It should be noted that this compound also inhibits PKCζ, meaning its effects on GSCs 
cannot be specifically attributed to PKCι. As we have shown that shRNA-mediated silencing of 
PKCι alone is sufficient to reduce the viability of GSCs, It would be interesting to test the effects 
of an inhibitor which is specific to PKCι only. PKCι has been very well studied in the context of 
NSCLC, and the aPKC inhibitor ATM, which is already in use in the clinic for rheumatoid arthritis, 
has recently been tested in a phase I dose escalation clinical trial in patients with advanced 
NSCLC, ovarian cancer and pancreatic cancer [32]. This inhibitor forms a thio-gold adduct with a 
cysteine residue in the Phox-bem1 (PB1) domain of PKCι, which prevents the interaction with 
Par6 and thereby inhibits the pro-oncogenic ERK signaling pathway [28]. However, we have 
shown that GSCs are less sensitive to ATM treatment than the lung cancer cell line A549, and 
that the compound does not cause a reduction of ERK signaling in GSCs. Although it cannot be 
ruled out that ATM is not taken up as readily by GSCs as A549 cells, this suggests that GSCs 
are not solely dependent on the ERK signaling pathway for survival.  
Therefore, we set out to investigate other possible roles of PKCι in GSCs, comparing gene 
expression of GSCs from two different patients transduced with lentiviral particles containing NT 
or PRKCI-targeting shRNA. This revealed the Notch signaling pathway as the most deregulated 
pathway in GSCs upon PRKCI silencing. Notch signaling is important in development and is 
associated with self-renewal, i.e. “stemness.” In fact, it has been shown that Notch activation 
contributes to glioma growth and survival [33], and that Notch signaling inhibition depletes GSCs 
and inhibits growth of tumor neurospheres and xenografts [34]. We have shown that the 
silencing of PRKCI and pharmacological inhibition of PKCι using the aPKC-PSP leads to 
reduced Notch signaling and increased cell death in GSCs, and that Notch1 and PKCι are in 
close proximity in GSCs, indicating that they may directly interact. Supportive of this, it has been 
shown in the developing chick central nervous system that both PKCι and PKCζ bind to Notch1 
and phosphorylate it at a distinct residue, leading to increased Notch signaling activity [35]. 
Furthermore, we have shown that the aPKC-PSP inhibitor, which inactivates PKCι by preventing 
its activation via the Thr555 phosphorylation, reduces Notch signaling, whereas ATM, rather 
functioning by blocking the interaction with PKCι and Par6, does not. This could also be 
indicative that the kinase activity of PKCι is important for its role in Notch signaling. Taken 
together, these data provide an attractive mechanism for how PKCι could modulate Notch 
signaling in GSCs, although further investigation would be required to confirm this. Interestingly, 
although the aforementioned study by Sjoqvist et al. shows that aPKCs and NUMB likely act on 
the Notch pathway at distinct steps, it has recently been suggested that PKCι knockout in 
embryonic mouse cells leads to enhanced generation of stem cells via inhibition of NUMB, and 
hence activation of the Notch pathway [36]. These data highlight that PKCι could affect Notch 
signaling differently in distinct cellular contexts. 
Kusne et al. demonstrated that targeting aPKC pharmacologically reduces tumor progression in 
mouse models of GBM using a GBM cell line and patient derived xenografts [21]. As it has  
recently been suggested, at least in the context of pancreatic cancer, that PKCι and PKCζ have 
non-redundant roles, it could be important to consider the aPKCs separately in cancer therapy 
[37]. Here, we showed that silencing PKCι (and not PKCζ) is sufficient to reduce tumor growth 
and increase survival in a highly aggressive mouse model using patient derived GSCs, and that 
the slowed growth is likely to be mediated via a depletion of Notch signaling. However, the 
tumors did not decrease in size, and the mice eventually succumbed to the disease. One reason 
for this could be that the doxycycline induced expression of PRKCI-sh2 did not achieve a 
sufficient knock-down of PKCι in the tumor. In addition, it is not surprising that tumors in which 
PKCι is knocked-down can eventually circumvent the effects of reduced levels of the protein, as 
PKCι has been shown to be involved in many different signaling axes, including MAP kinase, 
NF-κB and apoptosis [31]. Therefore targeting PKCι as a therapeutic option for GBM must be 
considered in combination with other targeted therapies, for example, Notch inhibitors and MAP 
kinase signaling inhibitors. Furthermore, traditional therapies to deplete the bulk of the tumor 
may also be necessary, as targeting PKCι may only diminish the GSC compartment of the 
tumor.  
In conclusion, we have shown that PKCι overexpression and -activation is cancer specific in a 
GSC context, and plays an important role for PKCι in GBM: namely the Notch signaling 
mediated survival of GSCs. The insensitivity of GSCs to the PB1 domain interaction-disrupting 
PKCι inhibitor ATM highlights the need for a different strategy for targeting PKCι in glioblastoma 
therapy, for example by preventing the activation of the kinase by blocking the phosphorylation 
of Thr555. 
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Figure Legends 
Figure 1: PKCι is overexpressed and activated in GSCs on the protein level. 
a) Representative Western blot showing PKCι or phospho- PKCι (Thr555) (active) levels in 
GSCs from three different patients (NCH421k, NCH644 and NCH441), human fetal 
neural stem cells (HFNSCs) and brain tissue lysate. α-Tubulin is shown as a loading 
control. 
b) PRKCI mRNA levels in GSCs from three different patients (NCH421k, NCH644 and 
NCH441), HFNSCs and brain tissue lysate, normalized to three different housekeeper 
genes (ARF1, DCTN2 and HPRT). (Experiment performed in technical triplicate). 
c) Levels of PRKCI 159 GBM cases compared with 8 normal controls [25]. Data was 
obtained from R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl). 
(***p<0.001, ns = not significant, one way analysis of variance [ANOVA]). 
 
Figure 2: PRKCI silencing induces apoptosis and reduces proliferation in GSCs. 
a) Protein levels in NCH421k 4 days after transduction with shNT or two different shRNAs 
against PRKCI, normalized to α-tubulin levels and to shNT PKCι levels (error bars 
indicate standard deviation [SD] of biological triplicates, *p<0.05, ***p<0.001, student’s t-
test). Inset: Representative Western blot showing PKCι protein levels with α-tubulin 
displayed as a loading control. 
b) Caspase assay showing caspase 3/7 activity in NCH421k, NCH644 and NCH441 GSCs 
4 days after transduction with shNT or two different shRNAs against PRKCI (error bars 
indicate SD of technical triplicates). 
c) Cell viability assay depicting percentage of living cells normalized to cells transduced 
with shNT. This was determined by a CellTiter-Glo® viability assay 5 days after 
transduction of NCH421k, NCH644 or NCH441 GSCs (black and gray bars) or HFNSCs 
(red bars) with shNT or two different shRNAs against PRKCI (error bars indicate SD of 
biological triplicates, *p<0.05, ns = not significant, student’s t-test). 
d) Cell proliferation assay showing percentage of NCH421k, NCH644 and NCH441 GSCs 
with incorporated EdU 4 days after transduction with shNT or two different shRNAs 
against PRKCI as determined by FACS analysis (error bars indicate SD of biological 
triplicates, *p<0.05, **p<0.01, ***p<0.001,   student’s t-test). 
Figure 3: Effects of pharmacological inhibition of PKCι on GSC viability 
a) Upper panel: Effect of aPKC pseudosubstrate peptide (aPKC-PSP) inhibitor on GSC 
NCH421k, NCH644 and NCH441 viability after incubation at the indicated concentrations 
for 3 days. Viability was normalized to cells incubated with the vehicle (H2O) (experiment 
was performed in technical duplicate). Lower panel: Levels of active PKCι were assessed 
by Western blot with an antibody against phospho-PKCι (Thr555). Levels of total PKCι 
are also shown and α-tubulin as a loading control. 
b) Upper panel: Effect of PKCι inhibitor ATM on GSC NCH421k, NCH644 and NCH441 
growth compared with lung cancer cell line A549 5 days after treatment at the indicated 
concentrations. Cell viability was normalized to cells incubated with vehicle (DMSO) 
(NCH421k and A549 were performed in biological triplicate, with error bars representing 
SD, *p<0.05, **p<0.01, student’s t-test, and NCH644 and NCH441 were performed in 
technical triplicate). Lower panel: ERK signaling activity was assessed at the indicated 
concentrations in NCH421k and A549 by Western blotting using the PathScan Multiplex 
Western Cocktail I, which contains anti phospho-ERK1/2 and Rab11 as a loading control.   
 
Figure 4: Gene expression profiling reveals Notch signaling to be downregulated in PRKCI-
silenced GSCs 
a) PRKCI was silenced using PRKCI-sh2 in GSCs from two different patients. Biological 
replicates were performed: twice in NCH421k and once in NCH644. Gene expression 
profiling was carried out 4 days after transduction. Pathway analysis of the most 
significant deregulated genes was carried out using Ingenuity Pathway Analysis 
Software. Bars represent the –log p-value of the significance of the pathway and the red 
line shows the ratio of genes deregulated in the pathway (*Benjamini-Hochberg adj. 
p<0.05, **B-H adj. p<0.01, ***B-H adj. p<0.001, right-tailed Fischer Exact test). 
b) Gene Set Enrichment Analysis (GSEA) revealed an overall downregulation of Notch 
signaling associated genes in PRKCI-silenced GSCs. The analysis was performed with 
the Notch Signaling Signature from Reactome as listed in the Molecular Signatures 
Database (http://www.broadinstitute.org/gsea/msigdb) in a rank order based on the mean 
linear fold change of the genes. Genes showing an upregulation after PRKCI knockdown 
are depicted in red and genes showing a downregulation depicted in blue. The green 
curve corresponds to the running sum of enrichment score which reflects the degree to 
which the Notch signature is overrepresented at the bottom of the list. Enrichment score 
(ES) = -0.48, normalized enrichment score (NES) = -1.67, false discovery rate (FDR) = 
0.001). 
c) mRNA levels of PRKCI and most down-regulated genes involved in Notch signaling 
(NOTCH1, NOTCH2, RBPJ and HES5) in NCH421k 4 days after transduction with shNT 
or two different shRNAs against PRKCI, normalized to 3 different housekeeper genes 
(ARF1, DCTN2 and HRPT) and to shNT expression levels (error bars indicate SD of 
biological triplicates, *p<0.05, *p<0.01, *p<0.001, student’s t-test). 
d) Protein levels of PKCι and the Notch Intracellular Domain (NICD) in NCH421k GSCs 4 
days after transduction with shNT or two different shRNAs against PRKCI, with α-tubulin 
displayed as a loading control. 
e) Left: Protein levels of PKCι phopsho-PKCι (Thr555) and the Notch Intracellular Domain 
(NICD) in NCH421k after 4 days of treatment with the aPKC pseudosubstrate peptide 
inhibitor (aPKC-PSP) at 0, 10 and 20 µM, with α-tubulin displayed as a loading control. 
Right: Quantification of the Western blot, normalized to α-tubulin and 0 µM sample. 
f) In situ proximity ligation assay (PLA) showing an increase of PLA signals in GSCs 
incubated with antibodies against PKCι and Notch1, compared with the single antibody 
controls (Representative experiment from biological triplicates, scale bar indicates 10 
µm, error bars indicate SD of 5 images). 
 
Figure 5: Doxycycline inducible shPRKCI GSC cell line overexpressing PRKCI enables 
apoptosis phenotype and Notch signaling reduction to be rescued 
a) Western blot analysis showing protein levels of PKCι in NCH644 GSCs with doxycycline 
inducible shNT or PRKCI-sh2 5 days after addition of doxycycline or PBS. α-Tubulin is 
shown as a loading control. 
b) Upper panel: Phenotype rescue. % PI positive cells were measured by FACS analysis 5 
days after doxycycline addition to NCH644 cells stably transduced with doxycycline 
inducible shNT or PRKCI-sh2 and constitutively expressing PKCι (or not) (error bars 
indicate SD of biological triplicates, *p<0.05, ns=not significant, student’s t-test). Lower 
panel: Notch signaling rescue: Western blot analysis showing PKCι (short and long 
exposure) and HES5 protein levels in the cells described in the left panel, with α-tubulin 
as a loading control. 
 
Figure 6: in vivo silencing of PRKCI slows tumour growth but does not cause tumor regression 
a) Tumor progression of mice after injection of NCH644 GSCs with doxycycline inducible 
shNT or PRKCI-sh2 based on luminescence flux. Two representative mice are shown. 
Nd = not determined as shNT mouse was sacrificed on day 24. 
b) Kaplan Meier graph showing the survival of mice after tumors had formed and 
doxycycline administered (or not in the case of the PRKCI-sh2-dox mice). Mice were 
given doxycycline via the water supply when the luminescence flux from the tumor 
reached 2.2x105 – 1.3x106. Mice were sacrificed when they began to display 
neuropathological symptoms (p*<0.05, p**<0.01, log rank (Mantel-Cox) test).  
c) Immunohistological staining of the tumors from the shNT+dox and PRKCI-sh2+dox mice 
shown in a) and a representative mouse from the PRKCI-sh2-dox group with antibodies 
against PKCι (upper panel) and HES5 (lower panel). Scale bar = 50 µm. 
 
